First-line chemotherapy for lung cancer has advanced with use of PD-1 inhibitors combined with cytotoxic chemotherapy and/or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody [18]. Here, PDCD1 is linked to lung carcinoma.